RPE65 and Leber congenital amaurosis: The first transformative step in ophthalmic gene therapy was the use of a recombinant adeno-associated virus (AAV) carrying RPE65-complementary DNA (cDNA) for patients with RPE65-associated Leber’s congenital amaurosis (LCA) [11].